コンテンツへスキップ
Merck

SAB4200815

Anti-VEGF165 antibody, Mouse monoclonal

clone VG-20, purified from hybridoma cell culture

別名:

VEGF-A, VPF, Vascular endothelial growth factor A, Vascular permeability factor

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

NACRES:
NA.41
UNSPSC Code:
12352203
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

製品名

Anti-VEGF165 antibody, Mouse monoclonal, clone VG-20, purified from hybridoma cell culture

biological source

mouse

conjugate

unconjugated

antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies

clone

VG-20, monoclonal

species reactivity

human

packaging

antibody small pack of 25 μL

concentration

~1 mg/mL

technique(s)

immunoblotting: 1-2 μg/mL using recombinant human VEGFA protein expressed in HEK-293

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... VEGF165(7422)

Application

The antibody is recommended to use in various immunological techniques, including Immunoblot (~21 kDa). Detection of the VEGF165 band by Immunoblotting is specifically inhibited by the immunogen.

Biochem/physiol Actions

Monoclonal Anti-VEGF165 specifically recognizes human VEGFA isoform VEGF165 and does not recognize VEGF121 isoform.
VEGF proteins are involved in angiogenesis and vasculogenesis, they predominantly activate proliferation and survival of endothelial cells and migration in non-endothelial cells.1VEGFA have several isoforms due to alternative splicing mainly at exons 6-8. The VEGF exon 8 splicing isoforms are divided into two groups, the “pro-angiogenic” VEGFxxxa isoforms considered to be activators of proliferation, survival and angiogenesis and the VEGFxxxb isoforms that are considered as “anti-angiogenic”.2

Disclaimer

Unless otherwise stated in our catalog our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

VEGFA - Vascular Endothelial Growth Factor A, also known as or Vascular permeability factor (VPF), is a major signaling growth factor member of the VEGF family, sub-group of the Platelet-Derived Growth Factor (PDFG) proteins, which is characterized by its conserved cystine-knot structure.1 VEGF expression is up regulated in hypoxia and in many types of cancers. Furthermore, VEGF receptors (VEGFR1 and VEGFR2) are also overexpressed in several tumors and studies have shown that high levels of VEGF correlates with poor prognosis.1-8 Inhibition of VEGF mediated angiogenesis signaling pathways have potential in angiogenesis-related disease therapy, this can be achieved by blocking either the circulating VEGF using Anti-VEGF antibodies such as Bevacizumab and Aflibercept5 or by VEGFR-2 inhibition using small molecules such as Gamabufotalin (CS-6) and Arenobufagin.6-8

Immunogen

Recombinant VEGF165 protein

Physical form

Supplied as a solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide as a preservative.

Preparation Note

For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Flavia Plastino et al.
Experimental eye research, 206, 108518-108518 (2021-02-28)
Echinomycin (EKN), an inhibitor of hypoxia-inducible factor (HIF)-1 DNA-binding activity, has been implied as a possible therapeutic agent in ischemic diseases. Here, we assess EKN in hypoxia-driven responses in vitro using human primary adult retinal pigment epithelium cells (aRPE) and
Pooja Yadav et al.
iScience, 26(6), 106804-106804 (2023-05-26)
Alternative splicing of vascular endothelial growth factor A (VEGFA) generates numerous isoforms with unique roles in tumor angiogenesis, and investigating the underlying mechanism during hypoxia necessitates diligent pursuance. Our research systematically demonstrated that the splicing factor SRSF2 causes the inclusion

関連コンテンツ

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)